Clinical characteristics of the 2 study cohorts
| Characteristics | Institutional Cohort (n = 86) | TCIA (n = 78) |
|---|---|---|
| Age (mean) (yr) | 60.9 ± 8.6 | 60.2 ± 7.6 |
| Sex (No.) (%) | ||
| Male | 78 (90.7) | 61 (78.2) |
| Female | 8 (9.3) | 17 (21.8) |
| Smoking history (No.) (%) | ||
| Smoker | 50 (58.1) | NA |
| Nonsmoker | 36 (41.9) | |
| HPV status (No.) (%) | ||
| Positive | 53 (61.6) | 23 (29.5) |
| Negative | 33 (38.4) | 55 (70.5) |
| T-stage (No.) (%) | ||
| I | 19 (22.1) | 13 (16.7) |
| II | 41 (47.7) | 24 (30.8) |
| III | 20 (23.3) | 10 (12.8) |
| IV | 6 (7.0) | 31 (39.7) |
| N-stage (No.) (%) | ||
| 0 | 18 (20.9) | 20 (25.6) |
| I | 32 (37.2) | 11 (14.1) |
| II | 33 (38.4) | 45 (57.7) |
| III | 3 (3.5) | 2 (2.6) |
| Overall stage (No.) (%) | ||
| I | 25 (29.1) | 5 (6.4) |
| II | 25 (29.1) | 7 (9) |
| III | 23 (26.7) | 10 (12.8) |
| IVA | 11 (12.8) | 49 (62.8) |
| IVB | 2 (2.3) | 7 (9) |
| No. of deaths (No.) (%) | 24 (27.9) | 45 (57.7) |
| Overall survival (mean) (day) | 1290.6 ± 883.4 | 2243.4 ± 1370.7 |
| Treatment (No.) (%) | ||
| Surgery | 60 (69.8) | 3 (3.8) |
| Chemotherapy | 56 (65.1) | NA |
| Radiation therapy | 60 (69.8) | 78 (100) |
Note:—NA indicates not applicable.